Long Position on SUPN @ $47.50 on 9/5/2017 (Momentum)

Supernus Pharmaceuticals, Inc. (SUPN) is a specialty pharmaceutical company.

The company focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States.

It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

The company's product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which has completed Phase IIb trial that is used for the treatment of ADHD.

It also develops SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression. The company markets its products through wholesalers and pharmaceutical distributors.

Shares are heading higher in an upward trading channel. Shares jumped recently following a four-day bench trial, that the United States District Court for the District of New Jersey ruled that TWi Pharmaceuticals, Inc. and its subsidiary infringed U.S. Patent Nos. 7,722,898, 7,910,131, and 8,821,930 by submitting to the FDA an Abbreviated New Drug Application (ANDA) seeking permission to market a generic version of Oxtellar XR before the expiration of Supernus’ patents. The formation is supported by the stock's 50-day moving average shown in brown.

52-Weeks Trading Range: $17.25 - $47.50

Entry Point: $47.50

Stop Loss: $45.70

Target Price: $52.10

Updates

9/19/2017 10:36:52 AM

SUPN closed at $45

Position closed on 9/19/2017 at price of $45.00 with a -5.26% loss in 14 days.

Back to Portfolio